Jacobio Pharmaceuticals Advances Pan-KRAS Inhibitor JAB-23E73 Through Clinical Development
Key Insights
Jacobio Pharmaceuticals (search) presented promising pre-clinical data for JAB-23E73, a highly potent pan-KRAS (search) inhibitor that demonstrates superior antitumor activity across multiple cancer (search) types with different KRAS mutations.
The compound induced tumor regression in KRAS (search)-driven mouse models without significant body weight loss, indicating good tolerability and a wide therapeutic window.
Phase I clinical trials are currently ongoing in China and the United States for patients with advanced solid tumors (search) harboring KRAS (search) gene alterations.
Jacobio Pharmaceuticals (search) Group Co., Ltd. (HK:1167) has advanced its pan-KRAS (search) inhibitor JAB-23E73 through clinical development, presenting encouraging pre-clinical data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer (search) Therapeutics while initiating Phase I clinical trials in multiple regions.
Pre-Clinical Results Demonstrate Potent Anti-Tumor Activity
The pre-clinical data revealed that JAB-23E73 is a highly potent pan-KRAS (search) (ON/OFF) inhibitor with strong selectivity that spares HRAS (search) and NRAS (search) inhibition. The compound exhibits superior antitumor activity across multiple cancer (search) types harboring different KRAS driver mutations or amplification.
In KRAS (search)-driven mouse tumor models, JAB-23E73 induced tumor regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also demonstrated a favorable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intratumoral p-ERK (search) inhibition.
Clinical Development Program Underway
Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors (search) harboring KRAS (search) gene alterations. The company is conducting a multicenter, open Phase I/IIa study titled "A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration."
The study is designed as an interventional, non-randomized trial following a sequential intervention model without masking. Its primary purpose is treatment-focused, aiming to establish the drug's safety and preliminary efficacy through two phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
Study Timeline and Design
Patient recruitment for the multicenter study is scheduled to begin on April 28, 2025. The orally administered drug will be tested in patients with advanced solid tumors (search) containing specific KRAS (search) genetic alterations. The study focuses on establishing optimal dosing while evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity.
Targeting a Challenging Oncology Target
The development of JAB-23E73 addresses KRAS (search) mutations, which represent a historically challenging target in oncology. KRAS mutations are among the most common oncogenic drivers in solid tumors, making effective inhibitors a significant unmet medical need in cancer (search) treatment.
Jacobio Pharma operates with an induced allosteric drug discovery platform, with core projects focused on the KRAS (search) pathway. The company's R&D centers are located in Beijing, Shanghai (China), and Boston (USA), with clinical trials conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.